home / stock / gikly / gikly news


GIKLY News and Press, Grifols SA Barcelona ADR From 01/17/24

Stock Information

Company Name: Grifols SA Barcelona ADR
Stock Symbol: GIKLY
Market: OTC
Website: grifols.com

Menu

GIKLY GIKLY Quote GIKLY Short GIKLY News GIKLY Articles GIKLY Message Board
Get GIKLY Alerts

News, Short Squeeze, Breakout and More Instantly...

GIKLY - Grifols' banking exposure under ECB scrutiny: Reuters

2024-01-17 14:56:12 ET More on Grifols S.A. Grifols: Wait And See For Now Grifols: I've Read The Short-Seller Report, And I Mostly Disagree Grifols Is Building Momentum ELAB, KIND and RLX among pre-market losers Haier Group still looking to buy Shangh...

GIKLY - Grifols Shareholder Action Reminder

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Grifols To Contact Him Directly To Discuss Their Options If you suffered significant losses in Grifols stock or options and would like to discuss your legal rights, call Faruqi & Faruq...

GIKLY - Grifols: Wait And See For Now

2024-01-10 13:15:00 ET Summary Gotham City's recent allegations against Grifols have caused GFRS stock to significantly decline. Our team at Mare will remain waiting for clarifications. We expect the company's stock to be under pressure in the short term and probably not investabl...

GIKLY - Grifols shares plunge after report on debt ratio concerns

2024-01-09 06:46:54 ET More on Grifols S.A. Grifols Is Building Momentum Grifols, S.A. (GRFS) Q3 2023 Earnings Call Transcript Grifols gains on plans to sell 20% of Shanghai RAAS stake to Haier Grifols said to be in talks for a partial sale of Shanghai RAAS ...

GIKLY - Doubling Down On Gain Therapeutics

2023-12-22 17:56:28 ET Summary The biotech bear market has presented investment opportunities for investors to take meaningful stakes in public companies at venture valuations. AI drug discovery has faced setbacks in the past 18 months, but Gain Therapeutics' has found success usi...

GIKLY - Grifols Is Building Momentum

2023-12-08 17:34:26 ET Summary Argenx's failure removes competitive pressure on Grifols' immunoglobulin franchise. Grifols is in advanced negotiations to sell Shanghai RAAS, which would eliminate short-term debt concerns. Grifols' Q3 results showed increased sales, improved EB...

GIKLY - Grifols said to be in talks for a partial sale of Shanghai RAAS

2023-11-29 08:21:29 ET More on Grifols Grifols, S.A. (GRFS) Q3 2023 Earnings Call Transcript Grifols: Cheap For A Reason Historical earnings data for Grifols, S.A. Financial information for Grifols, S.A. Historical earnings data for Grifols, S.A. ...

GIKLY - Grifols, S.A. (GRFS) Q3 2023 Earnings Call Transcript

2023-11-02 22:33:06 ET Grifols, S.A. (GRFS) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Nuria Pascual - IR and Sustainability Officer Thomas Glanzmann - Executive Chairman and CEO Victor Grifols Deu - COO Alfredo Arroyo -...

GIKLY - Grifols, S.A. (GRFS) Q2 2023 Earnings Call Transcript

2023-07-27 15:45:16 ET Grifols, S.A. (GRFS) Q2 2023 Earnings Conference Call July 27, 2023, 08:30 AM ET Company Participants Nuria Pascual - IR Thomas Glanzmann - our Executive Chairman and CEO Alfredo Arroyo - CFO Victor Grifols Deu - COO Conference Ca...

GIKLY - Grifols: A Promising Buy Opportunity

2023-07-05 10:56:31 ET Summary Grifols is a promising buy opportunity thanks to its potential to reduce its net debt/EBITDA ratio. The company's focus on deleveraging is showing results and is supported by higher savings and better margins. The plasma collection is also recovering...

Previous 10 Next 10